TRIM32
Basic information
Region (hg38): 9:116687305-116701300
Previous symbols: [ "LGMD2H" ]
Links
Phenotypes
GenCC
Source:
- Bardet-Biedl syndrome 11 (Definitive), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2H (Definitive), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2H (Supportive), mode of inheritance: AR
- Bardet-Biedl syndrome (Supportive), mode of inheritance: AR
- Bardet-Biedl syndrome 11 (Strong), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2H (Strong), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Bardet-Biedl syndrome 11 | AR | Endocrine | Medical management of obesity with melanocortin-4 receptor (MC4R) agonist (setmelanotide) may be beneficial | Craniofacial; Dermatologic; Gastrointestinal; Genitourinary; Endocrine; Musculoskeletal; Neurologic; Ophthalmologic; Renal | 4269389; 10399877; 11822024; 15886712; 15580560; 16243356; 15786463; 16606853; 17994549; 19492423; 20301537; 20177705; 21775502; 22981120; 36356613 |
ClinVar
This is a list of variants' phenotypes submitted to
- Bardet-Biedl syndrome (29 variants)
- not provided (4 variants)
- Sarcotubular myopathy (2 variants)
- Bardet-Biedl syndrome 11 (1 variants)
- Myopathy (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TRIM32 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 201 | 211 | ||||
missense | 296 | 301 | ||||
nonsense | 13 | 20 | ||||
start loss | 0 | |||||
frameshift | 19 | 11 | 30 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 30 | 40 | ||||
Total | 33 | 18 | 342 | 206 | 8 |
Highest pathogenic variant AF is 0.0000131
Variants in TRIM32
This is a list of pathogenic ClinVar variants found in the TRIM32 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
9-116687320-C-T | Sarcotubular myopathy • Bardet-Biedl syndrome 11 | Uncertain significance (Jan 13, 2018) | ||
9-116687330-G-C | Sarcotubular myopathy • Bardet-Biedl syndrome 11 | Benign (Jul 03, 2018) | ||
9-116687339-G-A | Bardet-Biedl syndrome 11 • Sarcotubular myopathy | Uncertain significance (Jan 12, 2018) | ||
9-116687354-T-C | Bardet-Biedl syndrome 11 • Sarcotubular myopathy | Uncertain significance (Jan 13, 2018) | ||
9-116687369-C-T | not specified | Likely benign (Sep 19, 2017) | ||
9-116687467-C-T | Benign (Apr 11, 2019) | |||
9-116697371-A-G | Likely benign (Dec 02, 2019) | |||
9-116697564-G-A | Benign (Jun 16, 2018) | |||
9-116697737-A-G | TRIM32-related disorder | Likely benign (Dec 08, 2021) | ||
9-116697738-G-A | TRIM32-related disorder | Uncertain significance (Sep 10, 2015) | ||
9-116697738-G-T | TRIM32-related disorder | Likely benign (Apr 17, 2024) | ||
9-116697748-T-G | Bardet-Biedl syndrome • not specified | Conflicting classifications of pathogenicity (Jan 30, 2024) | ||
9-116697753-C-T | Bardet-Biedl syndrome | Uncertain significance (Aug 10, 2022) | ||
9-116697757-A-C | Bardet-Biedl syndrome | Likely benign (May 19, 2023) | ||
9-116697762-C-T | Bardet-Biedl syndrome • TRIM32-related disorder | Uncertain significance (Jul 18, 2022) | ||
9-116697763-T-A | Bardet-Biedl syndrome | Likely benign (Oct 17, 2023) | ||
9-116697766-C-A | Bardet-Biedl syndrome • TRIM32-related disorder | Uncertain significance (Aug 23, 2022) | ||
9-116697769-G-A | Bardet-Biedl syndrome | Likely benign (Nov 03, 2022) | ||
9-116697769-G-C | Bardet-Biedl syndrome • Bardet-Biedl syndrome 11 • Sarcotubular myopathy | Conflicting classifications of pathogenicity (Jan 27, 2024) | ||
9-116697769-G-T | Bardet-Biedl syndrome | Likely benign (Jul 17, 2023) | ||
9-116697774-T-C | Bardet-Biedl syndrome • Bardet-Biedl syndrome 11;Sarcotubular myopathy • TRIM32-related disorder • Inborn genetic diseases | Uncertain significance (Jan 23, 2024) | ||
9-116697782-C-G | Uncertain significance (Jun 30, 2020) | |||
9-116697782-C-T | Bardet-Biedl syndrome | Uncertain significance (May 21, 2022) | ||
9-116697784-C-A | Bardet-Biedl syndrome | Likely benign (May 02, 2023) | ||
9-116697785-C-T | Bardet-Biedl syndrome • TRIM32-related disorder | Uncertain significance (Mar 02, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TRIM32 | protein_coding | protein_coding | ENST00000450136 | 1 | 13999 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00167 | 0.974 | 125697 | 0 | 51 | 125748 | 0.000203 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.827 | 335 | 380 | 0.881 | 0.0000245 | 4253 |
Missense in Polyphen | 93 | 125.72 | 0.73972 | 1505 | ||
Synonymous | 0.619 | 134 | 143 | 0.934 | 0.00000746 | 1392 |
Loss of Function | 1.98 | 7 | 15.4 | 0.455 | 8.06e-7 | 198 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000536 | 0.000535 |
Ashkenazi Jewish | 0.000596 | 0.000595 |
East Asian | 0.000272 | 0.000272 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000176 | 0.000176 |
Middle Eastern | 0.000272 | 0.000272 |
South Asian | 0.0000980 | 0.0000980 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Has an E3 ubiquitin ligase activity. Ubiquitinates DTNBP1 (dysbindin) and promotes its degradation. May ubiquitinate BBS2. May play a significant role in mediating the biological activity of the HIV-1 Tat protein in vivo. Binds specifically to the activation domain of HIV-1 Tat and can also interact with the HIV-2 and EIAV Tat proteins in vivo. {ECO:0000269|PubMed:19349376, ECO:0000269|PubMed:22500027}.;
- Disease
- DISEASE: Limb-girdle muscular dystrophy 2H (LGMD2H) [MIM:254110]: An autosomal recessive degenerative myopathy characterized by pelvic girdle, shoulder girdle and quadriceps muscle weakness. Clinical phenotype and severity are highly variable. Disease progression is slow and most patients remain ambulatory into the sixth decade of life. {ECO:0000269|PubMed:11822024, ECO:0000269|PubMed:17994549}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Bardet-Biedl syndrome 11 (BBS11) [MIM:615988]: A syndrome characterized by usually severe pigmentary retinopathy, early- onset obesity, polydactyly, hypogenitalism, renal malformation and mental retardation. Secondary features include diabetes mellitus, hypertension and congenital heart disease. Bardet-Biedl syndrome inheritance is autosomal recessive, but three mutated alleles (two at one locus, and a third at a second locus) may be required for clinical manifestation of some forms of the disease. {ECO:0000269|PubMed:16606853}. Note=The disease is caused by mutations affecting the gene represented in this entry. It has been suggested that TRIM32 might be the E3 ubiquitin ligase for BBS2, a component of the BBSome complex involved in ciliogenesis, that is ubiquitinated and degraded by the proteasome (PubMed:22500027). {ECO:0000269|PubMed:22500027}.;
- Pathway
- Ubiquitin mediated proteolysis - Homo sapiens (human);Regulation of innate immune responses to cytosolic DNA;Innate Immune System;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation;TNFalpha;Cytosolic sensors of pathogen-associated DNA
(Consensus)
Recessive Scores
- pRec
- 0.110
Intolerance Scores
- loftool
- 0.211
- rvis_EVS
- -0.6
- rvis_percentile_EVS
- 18.06
Haploinsufficiency Scores
- pHI
- 0.239
- hipred
- Y
- hipred_score
- 0.757
- ghis
- 0.526
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.983
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Trim32
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); reproductive system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; muscle phenotype; homeostasis/metabolism phenotype;
Zebrafish Information Network
- Gene name
- trim32
- Affected structure
- pronephric duct
- Phenotype tag
- abnormal
- Phenotype quality
- cystic
Gene ontology
- Biological process
- protein polyubiquitination;tissue homeostasis;ubiquitin-dependent protein catabolic process;actin ubiquitination;response to UV;protein ubiquitination;positive regulation of cell growth;positive regulation of cell migration;regulation of type I interferon production;negative regulation of viral transcription;response to tumor necrosis factor;positive regulation of I-kappaB kinase/NF-kappaB signaling;innate immune response;fat cell differentiation;positive regulation of neuron differentiation;positive regulation of protein catabolic process;positive regulation of cell cycle;positive regulation of proteolysis;muscle cell cellular homeostasis;negative regulation of fibroblast proliferation;positive regulation of neurogenesis;positive regulation of DNA-binding transcription factor activity;positive regulation of NF-kappaB transcription factor activity;positive regulation of striated muscle cell differentiation;axon development;protein K48-linked ubiquitination;negative regulation of viral release from host cell;negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage;positive regulation of tumor necrosis factor-mediated signaling pathway;positive regulation of nucleic acid-templated transcription;positive regulation of interleukin-17-mediated signaling pathway;positive regulation of chemokine (C-C motif) ligand 20 production;positive regulation of cell motility
- Cellular component
- nucleus;cytoplasm;cytosol;striated muscle myosin thick filament
- Molecular function
- transcription coactivator activity;RNA binding;ubiquitin-protein transferase activity;protein binding;zinc ion binding;myosin binding;Tat protein binding;translation initiation factor binding;identical protein binding;ubiquitin binding;protein self-association;ubiquitin protein ligase activity